Cosentyx (secukinumab) - Novartis
Cosentyx: Regulatory approval in China for psoriasis at the end of 2019 (Novartis) - May 25, 2019 - Investor Event: Regulatory approval in China for ankylosing spondylitis at the end of 2020 
Non-US regulatory
https://www.novartis.com/sites/www.novartis.com/files/2019-05-meet-novartis-management-presentation.pdf
 
May 25, 2019
 
 
728c9149-38ee-4b7d-b34e-72e5e0919c92.jpg